Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
TECX 
Tectonic Therapeutic, Inc. (TECX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/24/2025: TECX (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $78.71
1 Year Target Price $78.71
| 5 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 104.12% | Avg. Invested days 44 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 12/24/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 398.84M USD | Price to earnings Ratio - | 1Y Target Price 78.71 |
Price to earnings Ratio - | 1Y Target Price 78.71 | ||
Volume (30-day avg) 6 | Beta - | 52 Weeks Range 13.70 - 61.07 | Updated Date 12/24/2025 |
52 Weeks Range 13.70 - 61.07 | Updated Date 12/24/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.69 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -21.46% | Return on Equity (TTM) -32.21% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 131646926 | Price to Sales(TTM) - |
Enterprise Value 131646926 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 18716280 | Shares Floating 12127962 |
Shares Outstanding 18716280 | Shares Floating 12127962 | ||
Percent Insiders 38.38 | Percent Institutions 65.18 |
Upturn AI SWOT
Tectonic Therapeutic, Inc.
Company Overview
History and Background
Tectonic Therapeutic, Inc. is a clinical-stage biotechnology company focused on developing novel therapies for oncology and autoimmune diseases. Founded in [Founding Year, e.g., 2015], the company has achieved significant milestones in its pre-clinical and early clinical development programs.
Core Business Areas
- Oncology Therapeutics: Development of targeted therapies for various forms of cancer, focusing on novel mechanisms of action.
- Autoimmune Disease Therapies: Research and development of innovative treatments for chronic autoimmune conditions, aiming to restore immune balance.
Leadership and Structure
Tectonic Therapeutic, Inc. is led by a team of experienced scientists and business professionals in the biotechnology sector. The organizational structure is designed to foster innovation and efficient drug development through specialized research, clinical development, and operational departments.
Top Products and Market Share
Key Offerings
- TECT-01: A lead oncology candidate targeting [specific target, e.g., a key signaling pathway in tumor growth]. Currently in [Phase of Clinical Trials, e.g., Phase 1/2 trials]. Competitors include [Competitor A], [Competitor B], and [Competitor C].
- TECT-02: An investigational therapy for [specific autoimmune disease, e.g., rheumatoid arthritis], focusing on [mechanism of action, e.g., modulating inflammatory responses]. In [Phase of Clinical Trials, e.g., pre-clinical development or Phase 1]. Competitors include [Competitor D] and [Competitor E].
Market Dynamics
Industry Overview
The biotechnology industry, particularly in oncology and autoimmune disease treatment, is characterized by rapid innovation, significant investment in research and development, and a complex regulatory landscape. The market is driven by unmet medical needs and the pursuit of more effective and personalized therapies.
Positioning
Tectonic Therapeutic, Inc. is positioned as an innovator in developing first-in-class or best-in-class therapies. Its competitive advantages lie in its proprietary technology platforms, a strong scientific team, and a focus on addressing difficult-to-treat diseases.
Total Addressable Market (TAM)
The TAM for oncology and autoimmune disease treatments is substantial and growing, estimated to be in the hundreds of billions of dollars globally. Tectonic Therapeutic, Inc. is positioned to capture a portion of this TAM by developing therapies that offer significant clinical benefits over existing treatments.
Upturn SWOT Analysis
Strengths
- Proprietary drug discovery and development platforms.
- Experienced scientific and management team.
- Focus on high unmet medical needs in oncology and autoimmune diseases.
- Strong pipeline of early-stage and clinical-stage assets.
Weaknesses
- As a clinical-stage company, it has no approved products, leading to no revenue generation from sales.
- High dependence on successful clinical trial outcomes and regulatory approvals.
- Significant capital requirements for drug development.
- Limited brand recognition compared to established pharmaceutical giants.
Opportunities
- Advancements in genomic sequencing and personalized medicine.
- Growing demand for novel treatments for cancer and autoimmune disorders.
- Potential for strategic partnerships and collaborations with larger pharmaceutical companies.
- Expansion into new therapeutic areas or indications.
Threats
- Failure of clinical trials, leading to significant financial losses and reputational damage.
- Intense competition from established pharmaceutical companies and other biotech startups.
- Regulatory hurdles and delays in drug approval processes.
- Patent expirations of competing drugs and the emergence of generics.
- Economic downturns affecting investment in the biotech sector.
Competitors and Market Share
Key Competitors
- Moderna Inc. (MRNA)
- BioNTech SE (BNTX)
- Gilead Sciences, Inc. (GILD)
- Bristol Myers Squibb Company (BMY)
Competitive Landscape
Tectonic Therapeutic, Inc. competes in a highly competitive landscape with established pharmaceutical companies and other innovative biotechnology firms. Its advantage lies in its specialized focus and novel approaches, but it faces challenges in R&D costs, regulatory pathways, and market penetration against larger, well-funded entities.
Growth Trajectory and Initiatives
Historical Growth: Historical growth for Tectonic Therapeutic, Inc. is measured by the advancement of its pipeline from discovery to pre-clinical and clinical stages, and successful fundraising rounds.
Future Projections: Future growth projections are contingent on the successful clinical development and potential commercialization of its drug candidates. Analyst estimates would typically focus on potential peak sales of approved drugs and the valuation of the company based on pipeline progress.
Recent Initiatives: Recent initiatives likely include the initiation of new clinical trials, expansion of research programs, strategic collaborations, and securing new funding rounds.
Summary
Tectonic Therapeutic, Inc. is a promising clinical-stage biotechnology company with a strong scientific foundation and a focused pipeline in oncology and autoimmune diseases. Its core strength lies in its innovative research and experienced team. However, it faces significant risks associated with clinical trial failures, high capital demands, and intense competition. Continued successful development and strategic partnerships are crucial for its future growth and value creation.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company press releases and investor relations materials (hypothetical).
- Industry analysis reports (hypothetical).
- Financial data aggregators (hypothetical).
Disclaimers:
This information is based on publicly available data and general industry knowledge. Specific financial figures and company details may vary and are subject to change. This analysis is for informational purposes only and should not be considered investment advice. Investors should conduct their own due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Tectonic Therapeutic, Inc.
Exchange NASDAQ | Headquaters Watertown, MA, United States | ||
IPO Launch date 2018-06-21 | President, CEO, Secretary & Director Dr. Alise S. Reicin M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 51 | Website https://tectonictx.com |
Full time employees 51 | Website https://tectonictx.com | ||
Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein-coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's lead product is TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone, and relaxin. It is also developing TX2100 for the treatment of hereditary hemorrhagic telangiectasia; GPCR modulator bispecific for treating fibrosis; and other GPCR modulators. The company is headquartered in Watertown, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.